FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366998728> ?p ?o ?g. }

• W4366998728 endingPage "1004" @default.
• W4366998728 startingPage "996" @default.
• W4366998728 abstract "Randomized clinical trials of hypertension treatment intensity evaluate the effects on incident major adverse cardiovascular events (MACEs) and serious adverse events (SAEs). Occurrences after a non-fatal index event have not been rigorously evaluated. The aim of this study was to evaluate the association of intensive (<120 mmHg) to standard (<140 mmHg) blood pressure (BP) treatment with mortality mediated through a non-fatal MACE or non-fatal SAE in 9361 participants in the Systolic Blood Pressure Intervention Trial.Logistic regression and causal mediation modelling to obtain direct and mediated effects of intensive BP treatment. Primary outcome was all-cause mortality (ACM). Secondary outcomes were cardiovascular (CVM) and non-CV mortality (non-CVM). The direct effect of intensive treatment was a lowering of ACM [odds ratio (OR) 0.75, 95% confidence interval (CI): 0.60-0.94]. The MACE-mediated effect substantially attenuated (OR 0.96, 95% CI: 0.92-0.99) ACM, while the SAE-mediated effect was associated with increased (OR 1.03, 95% CI: 1.01-1.05) ACM. Similar patterns were noted for intensive BP treatment on CVM and non-CVM. We also noted that SAE incidence was 3.9-fold higher than MACE incidence (13.7 vs. 3.5%), and there were a total of 365 (3.9%) ACM cases, with non-CVM being 2.6-fold higher than CVM [2.81% (263/9361) vs. 1.09% (102/9361)]. The SAE to MACE and non-CVM to CVM preponderance was found across all age groups, with the ≥80-year age group having the highest differences.The current analytic techniques demonstrated that intensive BP treatment was associated with an attenuated mortality benefit when it was MACE-mediated and possibly harmful when it was SAE-mediated. Current cardiovascular trial reporting of treatment effects does not allow expansion of the lens to focus on important occurrences after the index event.The benefit of intensive (<120 mmHg) blood pressure (BP) treatment, reduction in all-cause mortality (ACM), was attenuated when mediated through non-fatal major adverse cardiovascular events. This was driven by cardiovascular mortality (CVM). The harm of intensive BP treatment, increase in ACM, was amplified when mediated through serious adverse events. This was driven by non-CVM. Current reporting of treatment effects in cardiovascular trials does not allow for expansion of the lens to focus on important occurrences after the index event." @default.
• W4366998728 created "2023-04-27" @default.
• W4366998728 creator A5000351033 @default.
• W4366998728 creator A5017250194 @default.
• W4366998728 creator A5021094428 @default.
• W4366998728 creator A5031229218 @default.
• W4366998728 creator A5048574696 @default.
• W4366998728 creator A5052978037 @default.
• W4366998728 creator A5064612687 @default.
• W4366998728 creator A5073967906 @default.
• W4366998728 creator A5088792900 @default.
• W4366998728 creator A5089819618 @default.
• W4366998728 date "2023-04-25" @default.
• W4366998728 modified "2023-10-14" @default.
• W4366998728 title "The association of intensive blood pressure treatment and non-fatal cardiovascular or serious adverse events in older adults with mortality: mediation analysis in SPRINT" @default.
• W4366998728 cites W1414326081 @default.
• W4366998728 cites W2092075924 @default.
• W4366998728 cites W2146050890 @default.
• W4366998728 cites W2152933085 @default.
• W4366998728 cites W2363773630 @default.
• W4366998728 cites W2402203869 @default.
• W4366998728 cites W2614502717 @default.
• W4366998728 cites W2768267412 @default.
• W4366998728 cites W2795250807 @default.
• W4366998728 cites W2800121660 @default.
• W4366998728 cites W2895692833 @default.
• W4366998728 cites W2914508465 @default.
• W4366998728 cites W2974258030 @default.
• W4366998728 cites W3012685642 @default.
• W4366998728 cites W3017833396 @default.
• W4366998728 cites W3044943384 @default.
• W4366998728 cites W3046806428 @default.
• W4366998728 cites W3150595609 @default.
• W4366998728 cites W4200035029 @default.
• W4366998728 cites W4200035084 @default.
• W4366998728 doi "https://doi.org/10.1093/eurjpc/zwad132" @default.
• W4366998728 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37185634" @default.
• W4366998728 hasPublicationYear "2023" @default.
• W4366998728 type Work @default.
• W4366998728 citedByCount "0" @default.
• W4366998728 crossrefType "journal-article" @default.
• W4366998728 hasAuthorship W4366998728A5000351033 @default.
• W4366998728 hasAuthorship W4366998728A5017250194 @default.
• W4366998728 hasAuthorship W4366998728A5021094428 @default.
• W4366998728 hasAuthorship W4366998728A5031229218 @default.
• W4366998728 hasAuthorship W4366998728A5048574696 @default.
• W4366998728 hasAuthorship W4366998728A5052978037 @default.
• W4366998728 hasAuthorship W4366998728A5064612687 @default.
• W4366998728 hasAuthorship W4366998728A5073967906 @default.
• W4366998728 hasAuthorship W4366998728A5088792900 @default.
• W4366998728 hasAuthorship W4366998728A5089819618 @default.
• W4366998728 hasBestOaLocation W43669987281 @default.
• W4366998728 hasConcept C120665830 @default.
• W4366998728 hasConcept C121332964 @default.
• W4366998728 hasConcept C126322002 @default.
• W4366998728 hasConcept C151956035 @default.
• W4366998728 hasConcept C156957248 @default.
• W4366998728 hasConcept C168563851 @default.
• W4366998728 hasConcept C197934379 @default.
• W4366998728 hasConcept C2780400711 @default.
• W4366998728 hasConcept C2780739214 @default.
• W4366998728 hasConcept C44249647 @default.
• W4366998728 hasConcept C500558357 @default.
• W4366998728 hasConcept C61511704 @default.
• W4366998728 hasConcept C71924100 @default.
• W4366998728 hasConcept C84393581 @default.
• W4366998728 hasConceptScore W4366998728C120665830 @default.
• W4366998728 hasConceptScore W4366998728C121332964 @default.
• W4366998728 hasConceptScore W4366998728C126322002 @default.
• W4366998728 hasConceptScore W4366998728C151956035 @default.
• W4366998728 hasConceptScore W4366998728C156957248 @default.
• W4366998728 hasConceptScore W4366998728C168563851 @default.
• W4366998728 hasConceptScore W4366998728C197934379 @default.
• W4366998728 hasConceptScore W4366998728C2780400711 @default.
• W4366998728 hasConceptScore W4366998728C2780739214 @default.
• W4366998728 hasConceptScore W4366998728C44249647 @default.
• W4366998728 hasConceptScore W4366998728C500558357 @default.
• W4366998728 hasConceptScore W4366998728C61511704 @default.
• W4366998728 hasConceptScore W4366998728C71924100 @default.
• W4366998728 hasConceptScore W4366998728C84393581 @default.
• W4366998728 hasFunder F4320306230 @default.
• W4366998728 hasFunder F4320337337 @default.
• W4366998728 hasFunder F4320337338 @default.
• W4366998728 hasIssue "10" @default.
• W4366998728 hasLocation W43669987281 @default.
• W4366998728 hasLocation W43669987282 @default.
• W4366998728 hasOpenAccess W4366998728 @default.
• W4366998728 hasPrimaryLocation W43669987281 @default.
• W4366998728 hasRelatedWork W2037611947 @default.
• W4366998728 hasRelatedWork W2138334887 @default.
• W4366998728 hasRelatedWork W2218945907 @default.
• W4366998728 hasRelatedWork W2325084897 @default.
• W4366998728 hasRelatedWork W2335988042 @default.
• W4366998728 hasRelatedWork W2417485714 @default.
• W4366998728 hasRelatedWork W2971695752 @default.
• W4366998728 hasRelatedWork W2981372489 @default.
• W4366998728 hasRelatedWork W3010075638 @default.
• W4366998728 hasRelatedWork W4322739880 @default.

• next